BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31737133)

  • 1. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
    Huang C; Han W; Wang C; Liu Y; Chen Y; Duan Z
    Dis Markers; 2019; 2019():9121207. PubMed ID: 31737133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].
    Huang CY; Liu YM; Liu H; Xu B; Yan HP; Zhang HP; Liao HY; Zhang XD; Zhao J; Li WJ; Duan ZP
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):419-425. PubMed ID: 35545568
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.
    Nakamura M; Shimizu-Yoshida Y; Takii Y; Komori A; Yokoyama T; Ueki T; Daikoku M; Yano K; Matsumoto T; Migita K; Yatsuhashi H; Ito M; Masaki N; Adachi H; Watanabe Y; Nakamura Y; Saoshiro T; Sodeyama T; Koga M; Shimoda S; Ishibashi H
    J Hepatol; 2005 Mar; 42(3):386-92. PubMed ID: 15710222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.
    Nakamura M; Kondo H; Mori T; Komori A; Matsuyama M; Ito M; Takii Y; Koyabu M; Yokoyama T; Migita K; Daikoku M; Abiru S; Yatsuhashi H; Takezaki E; Masaki N; Sugi K; Honda K; Adachi H; Nishi H; Watanabe Y; Nakamura Y; Shimada M; Komatsu T; Saito A; Saoshiro T; Harada H; Sodeyama T; Hayashi S; Masumoto A; Sando T; Yamamoto T; Sakai H; Kobayashi M; Muro T; Koga M; Shums Z; Norman GL; Ishibashi H
    Hepatology; 2007 Jan; 45(1):118-27. PubMed ID: 17187436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report.
    Zhao DT; Liu YM; Han Y; Zhang HP; Zhao Y; Yan HP
    Medicine (Baltimore); 2020 Jan; 99(3):e18856. PubMed ID: 32011506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of antinuclear antibodies in primary biliary cirrhosis.
    Gao L; Tian X; Liu B; Zhang F
    Clin Exp Med; 2008 Mar; 8(1):9-15. PubMed ID: 18385935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.
    Itoh S; Ichida T; Yoshida T; Hayakawa A; Uchida M; Tashiro-Itoh T; Matsuda Y; Ishihara K; Asakura H
    J Gastroenterol Hepatol; 1998 Mar; 13(3):257-65. PubMed ID: 9570238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
    Qian JD; Yao TT; Wang Y; Wang GQ
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis.
    Nakamura M; Takii Y; Ito M; Komori A; Yokoyama T; Shimizu-Yoshida Y; Koyabu M; Matsuyama M; Mori T; Kamihira T; Daikoku M; Migita K; Yatsuhashi H; Nozaki N; Shimoda S; Ishibashi H
    J Autoimmun; 2006 Mar; 26(2):138-45. PubMed ID: 16337775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peri-nuclear antibodies correlate with survival in Greek primary biliary cirrhosis patients.
    Sfakianaki O; Koulentaki M; Tzardi M; Tsangaridou E; Theodoropoulos PA; Castanas E; Kouroumalis EA
    World J Gastroenterol; 2010 Oct; 16(39):4938-43. PubMed ID: 20954280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis.
    Hu SL; Zhao FR; Hu Q; Chen WX
    PLoS One; 2014; 9(7):e101916. PubMed ID: 25010534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and impact of Sjögren's syndrome in primary biliary cholangitis: a systematic review and meta-analysis.
    Deng X; Li J; Hou S; Ci B; Liu B; Xu K
    Ann Hepatol; 2022; 27(6):100746. PubMed ID: 35970319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis.
    Imura-Kumada S; Hasegawa M; Matsushita T; Hamaguchi Y; Encabo S; Shums Z; Norman GL; Takehara K; Fujimoto M
    Mod Rheumatol; 2012 Nov; 22(6):892-8. PubMed ID: 22327744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis.
    Luettig B; Boeker KH; Schoessler W; Will H; Loges S; Schmidt E; Worman HJ; Gershwin ME; Manns MP
    J Hepatol; 1998 May; 28(5):824-8. PubMed ID: 9625318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker?
    Sun C; Xiao X; Yan L; Sheng L; Wang Q; Jiang P; Lian M; Li Y; Wei Y; Zhang J; Chen Y; Li B; Li Y; Huang B; Li Y; Peng Y; Chen X; Fang J; Qiu D; Hua J; Tang R; Leung P; Gershwin ME; Miao Q; Ma X
    J Autoimmun; 2019 May; 99():33-38. PubMed ID: 30709684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased sensitivity of gp210 autoantibody detection using a newly designed gp210 antigen.
    Xu J; Zhang H; Wang C; Jiang P; Han C; Dai Y; Qiu F; Gong Y; Jiang Y; Xu P; Zhang M; Zhang L; Shi X; Chen S; Tian Y; Seldin MF; Gershwin ME; Liu X; Li L
    J Immunol Methods; 2022 Feb; 501():113211. PubMed ID: 34971632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
    Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
    J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
    Wang Z; Li Y; Ren L; Li Y; Xu T; Li W; Gao W; Sun G; Liu M
    Immun Inflamm Dis; 2024 Jan; 12(1):e1161. PubMed ID: 38270327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
    Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
    Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Baseline analysis of refractory primary biliary cirrhosis].
    Wang L; Kong F; Zhang X; Xu D; Hu ZJ; Li YZ; Zhang FC
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2918-20. PubMed ID: 23328240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.